查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553435

藥品監管事務 (RA) 市場規模、佔有率、趨勢分析報告：按服務供應商、按服務、按類別、按適應症、按發展階段、按公司規模、按地區、細分市場趨勢：2024-2030

Pharmaceutical Regulatory Affairs Market Size, Share & Trends Analysis Report By Service Provider, By Service, By Category, By Indication, By Development Stage, By Company Size, By Region, and Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

藥品監管事務 (RA) 市場成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球藥品監管事務 (RA) 市場規模預計將達到 143.4 億美元。

預計2024年至2030年複合年成長率為7.16%。推動市場成長的主要因素是不斷變化的監管環境以及個人化醫療、生物相似藥和孤兒藥等新興領域的成長。 FDA 的醫藥品認證過程正在發生重大變化。最近通過的《21 世紀治癒法案》預計將加快 FDA 對某些類型藥物的核准流程。

FDA 啟動了四個計劃（加速核准、優先審查、快速通道和突破性治療），以加快對治療嚴重和危及生命的疾病的藥物的審查。這些計劃下的藥物可以更快獲得監管機構的核准。此外，英國還啟動了“加速獲取合作”，這是一項由政府主導的舉措，旨在加速患者獲得突破性新藥，預計將提高該國新療法的可用性和可及性。核准流程中的這些變更預計將推動創新，並增加對熟悉全球核准流程近期變化的監管服務供應商的需求。

隨著生物相似藥、孤兒藥、個人化藥物、伴同性診斷、適應性研究設計和其他產品市場的成長，這些領域對監管專業知識的需求預計將會增加。隨著公司向其他行業擴張並面臨日益增加的監管合規負擔，對具有業務知識的專業服務供應商的需求不斷增加。特別是在新興經濟體，政府資助大大加速了孤兒藥的開發。

多家公司正在透過聯盟、收購和新產品開發來獲得市場地位。例如，Freya於2022年10月與韓國整形外科植入製造商合作，根據協議提供監管器械註冊和法律代表服務。此外，2022 年 1 月，Parexel International Corporation 成立了監管和准入諮詢組織。該組織的成立是為了從臨床試驗的早期階段提供監管支持。

藥品監管事務 (RA) 市場報告亮點

  • 分品類來看，醫藥部門銷售額佔比最大，2023年佔比超過55.36%。人口成長、都市化進程加快以及國內對優質醫療保健的需求不斷增加，為製藥公司開發和生產創新藥物創造了重大機會。
  • 按類別分類，由於瘧疾、愛滋病毒/愛滋病和非傳染性疾病等疾病的流行，預計生物製藥產業在預測期內的複合年成長率將達到 9.07%。
  • 有跡象表明，免疫學領域預計在預測期內成長最快，複合年成長率為 10.34%。製藥和生物製藥公司強大的免疫學產品線預計將進一步推動該行業的成長。
  • 2023年，腫瘤領域市場佔有率最大，為32.98%。這可能是由於癌症的高盛行率以及對安全有效的治療方案的需求不斷成長。
  • 依產品階段分類，臨床試驗細分市場佔最大市場佔有率，2023年為44.14%。這是由於臨床試驗註冊數量的增加，預計將推動該細分市場的成長。
  • 預計臨床前測試領域在預測期內將以 8.40% 的複合年成長率成長最快。癌症、心血管疾病和神經系統疾病等已有疾病的盛行率不斷上升是推動市場成長的因素。
  • 按服務供應商，外包監管產業預計在 2023 年佔據最大市場佔有率，達到 58.16%，預測期內複合年成長率最快為 8.76%。這些服務越來越受歡迎的原因是外包使醫療保健公司能夠降低成本，這是市場成長的關鍵驅動力。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 藥品監管事務 (RA) 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 配套市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 服務差距分析
    • 市場機會
    • 市場問題分析
  • 2023 年臨床試驗數量分析
    • 按地區分類的臨床試驗總數（2023 年）
    • 臨床試驗總數（按階段）（2023年）
    • 臨床試驗總數（依研究設計）（2023）
    • 按主要治療領域分類的臨床試驗總數（2023 年）
  • 藥品監管事務 (RA) 市場：分析工具
    • 波特五力分析
    • PESTEL分析
  • COVID-19 影響分析
  • 監管事務 (RA) 服務的最佳實踐和案例研究

第 4 章 藥品監管事務 (RA) 市場：服務供應商的估計和趨勢分析

  • 細分儀表板
  • 全球藥品監管事務（RA）市場波動分析
  • 全球藥品監管事務 (RA) 市場規模和趨勢分析（按服務供應商），2018-2030 年
  • 公司內部
  • 外包

第5章 藥品監管事務 (RA) 市場：按服務分類的估計和趨勢分析

  • 細分儀表板
  • 全球藥品監管事務（RA）市場波動分析
  • 2018-2030 年全球藥品監管事務 (RA) 市場規模及趨勢分析（按服務）
  • 監理諮詢
  • 法律代表
  • 撰寫和發布規範文件
  • 產品註冊及臨床試驗申請
  • 其他服務

第6章 藥品監管事務（RA）市場：按類別估計和趨勢分析

  • 細分儀表板
  • 全球藥品監管事務（RA）市場波動分析
  • 2018-2030 年全球藥品監管事務 (RA) 市場規模及趨勢分析（按類別）
  • 藥物
  • 生物製藥

第7章 藥品監管事務（RA）市場：按指標估計和趨勢分析

  • 細分儀表板
  • 全球藥品監管事務（RA）市場波動分析
  • 2018-2030 年全球藥品監管事務 (RA) 市場規模與趨勢分析、適應症
  • 腫瘤學
  • 神經病學
  • 心臟病學
  • 免疫學
  • 其他

第8章 藥品監管事務（RA）市場：按發展階段的估計和趨勢分析

  • 細分儀表板
  • 全球藥品監管事務（RA）市場波動分析
  • 2018-2030年全球藥品監理事務（RA）市場規模及趨勢分析、發展階段
  • 臨床前
  • 臨床研究
  • 上市後核准(PMA)

第9章 藥品監管事務（RA）市場：按公司規模分類的估計和趨勢分析

  • 細分儀表板
  • 全球藥品監管事務（RA）市場波動分析
  • 2018-2030年全球藥品監理事務（RA）市場規模及趨勢分析、公司規模
  • 小規模
  • 中等尺寸
  • 大規模

第10章藥品監管事務（RA）市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 2018 年至 2030 年市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018 年至 2030 年市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 荷蘭
    • 瑞士
    • 瑞典
  • 亞太地區
    • 2018 年至 2030 年市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 印尼
    • 馬來西亞
    • 新加坡
    • 泰國
    • 台灣
  • 拉丁美洲
    • 2018 年至 2030 年市場估計與預測
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
  • 中東
    • 2018 年至 2030 年市場估計與預測
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 埃及
    • 以色列
  • 非洲
    • 2018 年至 2030 年市場估計與預測
    • 南非
    • 波札那
    • 奈米比亞
    • 辛巴威
    • 尚比亞
    • 坦尚尼亞
    • 盧安達
    • 迦納
    • 奈及利亞
    • 烏干達
    • 模里西斯
    • 肯亞

第11章競爭格局

  • 市場參與企業分類
    • 市場領導者
    • 新興企業
  • 競爭市場評估分析（2023）
  • 服務熱圖分析（公司比較分析）
  • 公司簡介
    • Freyr
    • IQVIA Inc.
    • ICON plc.
    • WuXi AppTec（WAI）
    • Charles River Laboratories International, Inc.
    • Labcorp Drug Development
    • Parexel International Corporation
    • Pharmalex GmbH
    • Pharmexon
    • Genpact
Product Code: GVR-4-68040-107-1

Pharmaceutical Regulatory Affairs Market Growth & Trends:

The global pharmaceutical regulatory affairs market size is expected to reach USD 14.34 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.16% from 2024 to 2030. The key factors driving the market growth are the changing regulatory landscape and growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs. There have been significant changes to the FDA's drug approval processes. Recently, the 21st Century Cures bill was passed, which is expected to speed up the approval process of the FDA for certain types of drugs.

The FDA has launched four programs-Accelerated Approval, Priority Review, Fast Track, and Breakthrough Therapy-to expedite drug reviews for serious and life-threatening diseases. The medicines under these programs are approved faster by regulatory agencies. In addition, in the UK, the launch of The Accelerated Access Collaborative, a government initiative to fast-track patient access to potential breakthrough medicines, is anticipated to boost the availability and accessibility of novel therapies in the country. These changes in approval processes are expected to drive innovation and increase the demand for regulatory service providers who are well-acquainted with recent changes in approval processes globally.

The demand for regulatory specialization in these fields is anticipated to increase with the growth of the markets for biosimilar, orphan medications, personalized medicines, companion diagnostics, adaptive trial designs, and other products. Demand for specialized service providers with expertise in regulatory affairs is increasing as companies expand into different industries and face a growing burden of regulatory compliance. Government financing has considerably accelerated the development of orphan medications, particularly in industrialized economies.

Several companies are involved in collaborations, acquisitions, and new product development to gain a position in the market. For instance, in October 2022, Freyr partnered with an orthopedic implant manufacturing company in Korea, and as per the agreement, provided it with regulatory device registration and legal representation services. Moreover, in January 2022, Parexel International Corporation formed a Regulatory & Access Consulting Organization. This organization was established to provide regulatory support to clinical studies from the early stages.

Pharmaceutical Regulatory Affairs Market Report Highlights:

  • In terms of category, the drug segment held the largest revenue share of over 55.36% in 2023. The growing population, increasing urbanization, and rising demand for quality healthcare in the country have created a significant potential for pharmaceutical companies that develop and manufacture innovative drugs
  • Based on category, the biologics segment is anticipated to register the fastest CAGR of 9.07% over the forecast period owing to the prevalence of diseases such as malaria, HIV/AIDS, and non-communicable diseases
  • In terms of indication, the immunology segment is projected to grow at the fastest CAGR of 10.34% over the forecast period. The robust immunology pipeline of pharmaceutical and biopharmaceutical companies is anticipated to further boost segment growth
  • The oncology segment dominated the market in 2023 with the largest revenue share of 32.98%. This can be attributed to the high prevalence of cancer, which is boosting the need for safe and effective treatment options
  • In terms of product stage, the clinical studies segment held the largest market share of 44.14% % in 2023. This can be attributed to the increasing number of clinical trial registrations, which is expected to drive the segment growth
  • The preclinical segment is projected to grow at the fastest CAGR of 8.40% during the forecast period. Increasing prevalence of existing diseases such as cancer, CVDs, & neurological diseases are factors driving the market growth
  • In terms of service providers, the outsourced regulatory affairs segment held the largest market share in 2023 at 58.16% % and is anticipated to witness the fastest CAGR of 8.76% over the forecast period. The increasing popularity of these services can be attributed to the fact that outsourcing enables healthcare companies to reduce costs, which is a major contributing factor to market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Regulatory Affairs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Changing Regulatory Landscape
      • 3.2.1.2. Life Sciences Companies Focusing on Their Core Competencies
      • 3.2.1.3. Economic and Competitive Pressures
      • 3.2.1.4. Demand for the Faster Approval Process for Breakthrough Drugs and Devices
      • 3.2.1.5. Entry of Companies into the Global Market
      • 3.2.1.6. Growth in Emerging Areas such as Personalized Medicine, Biosimilars, and Orphan Drugs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Risk Associated with Data Security
      • 3.2.2.2. Monitoring Issues and Lack of Standardization
  • 3.3. Service Gap Analysis
    • 3.3.1. Market Opportunities
      • 3.3.1.1. Service Upgrade
      • 3.3.1.2. Technological Advancements
      • 3.3.1.3. Latest Trends
    • 3.3.2. Market Challenges Analysis
      • 3.3.2.1. Analysis Pertaining to Existing Gaps & Shortcomings in the Regulatory Services
      • 3.3.2.2. Bottlenecks Faced by Companies Seeking Regulatory Approvals or Maintaining Compliance
  • 3.4. Clinical Trials Volume Analysis, 2023
    • 3.4.1. Total Number of Clinical Trials, by Region (2023)
    • 3.4.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.4.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.4.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.5. Pharmaceutical Regulatory Affairs Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
  • 3.6. COVID-19 Impact Analysis
  • 3.7. Best Practices and Case Study Pertaining to Regulatory Affairs Services

Chapter 4. Pharmaceutical Regulatory Affairs Market: Service Provider Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
  • 4.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
  • 4.4. In-house
    • 4.4.1. In-house Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Outsourcing
    • 4.5.1. Outsourcing Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Regulatory Affairs Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
  • 5.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Regulatory Consulting
    • 5.4.1. Regulatory Consulting Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Legal Representation
    • 5.5.1. Legal Representation Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Regulatory Writing & Publishing
    • 5.6.1. Regulatory Writing & Publishing Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Writing
      • 5.6.2.1. Writing Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.6.3. Publishing
      • 5.6.3.1. Publishing Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Product Registration & Clinical Trial Applications
    • 5.7.1. Product Registration & Clinical Trial Applications Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8. Other Services
    • 5.8.1. Other Services Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Regulatory Affairs Market: Category Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
  • 6.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
  • 6.4. Drugs
    • 6.4.1. Drugs Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Innovator
      • 6.4.2.1. Innovator Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. Preclinical
        • 6.4.2.2.1. Preclinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. Clinical
        • 6.4.2.3.1. Clinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Post Market Approval (PMA)
        • 6.4.2.4.1. Post Market Approval (PMA) Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Generics
      • 6.4.3.1. Generics Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.4.3.2. Preclinical
        • 6.4.3.2.1. Preclinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.4.3.3. Clinical
        • 6.4.3.3.1. Clinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.4.3.4. Post Market Approval (PMA)
        • 6.4.3.4.1. Post Market Approval (PMA) Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Biologics
    • 6.5.1. Biologics Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Biotech
      • 6.5.2.1. Biotech Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.2.2. Preclinical
        • 6.5.2.2.1. Preclinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.2.3. Clinical
        • 6.5.2.3.1. Clinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.2.4. Post Market Approval (PMA)
        • 6.5.2.4.1. Post Market Approval (PMA) Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. ATMP
      • 6.5.3.1. ATMP Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.3.2. Preclinical
        • 6.5.3.2.1. Preclinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.3.3. Clinical
        • 6.5.3.3.1. Clinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.3.4. Post Market Approval (PMA)
        • 6.5.3.4.1. Post Market Approval (PMA) Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Biosimilars
      • 6.5.4.1. Biosimilars Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.4.2. Preclinical
        • 6.5.4.2.1. Preclinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.4.3. Clinical
        • 6.5.4.3.1. Clinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
      • 6.5.4.4. Post Market Approval (PMA)
        • 6.5.4.4.1. Post Market Approval (PMA) Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical Regulatory Affairs Market: Indication Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
  • 7.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Indication, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Neurology
    • 7.5.1. Neurology Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Cardiology
    • 7.6.1. Cardiology Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7. Immunology
    • 7.7.1. Immunology Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical Regulatory Affairs Market: Development Stage Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
  • 8.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Development Stage, 2018 to 2030 (USD Million)
  • 8.4. Preclinical
    • 8.4.1. Preclinical Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5. Clinical studies
    • 8.5.1. Clinical Studies Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6. Post Market Approval (PMA)
    • 8.6.1. Post Market Approval (PMA) Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 9. Pharmaceutical Regulatory Affairs Market: Company Size Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Pharmaceutical Regulatory Affairs Market Movement Analysis
  • 9.3. Global Pharmaceutical Regulatory Affairs Market Size & Trend Analysis, Company Size, 2018 to 2030 (USD Million)
  • 9.4. Small
    • 9.4.1. Small Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 9.5. Medium
    • 9.5.1. Medium Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 9.6. Large
    • 9.6.1. Large Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 10. Pharmaceutical Regulatory Affairs Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Scenario
      • 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Scenario
      • 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Scenario
      • 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Scenario
      • 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Scenario
      • 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Scenario
      • 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Scenario
      • 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Scenario
      • 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Scenario
      • 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.8. Norway
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Scenario
      • 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.9. The Netherlands
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Scenario
      • 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.10. Switzerland
      • 10.5.10.1. Key Country Dynamics
      • 10.5.10.2. Competitive Scenario
      • 10.5.10.3. Regulatory Scenario
      • 10.5.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.11. Sweden
      • 10.5.11.1. Key Country Dynamics
      • 10.5.11.2. Competitive Scenario
      • 10.5.11.3. Regulatory Scenario
      • 10.5.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.2. Japan
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Scenario
      • 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.3. China
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Scenario
      • 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Scenario
      • 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Scenario
      • 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Scenario
      • 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.7. Indonesia
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Scenario
      • 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.8. Malaysia
      • 10.6.8.1. Key Country Dynamics
      • 10.6.8.2. Competitive Scenario
      • 10.6.8.3. Regulatory Scenario
      • 10.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.9. Singapore
      • 10.6.9.1. Key Country Dynamics
      • 10.6.9.2. Competitive Scenario
      • 10.6.9.3. Regulatory Scenario
      • 10.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.10. Thailand
      • 10.6.10.1. Key Country Dynamics
      • 10.6.10.2. Competitive Scenario
      • 10.6.10.3. Regulatory Scenario
      • 10.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.11. Taiwan
      • 10.6.11.1. Key Country Dynamics
      • 10.6.11.2. Competitive Scenario
      • 10.6.11.3. Regulatory Scenario
      • 10.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Scenario
      • 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Scenario
      • 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.4. Colombia
      • 10.7.4.1. Key Country Dynamics
      • 10.7.4.2. Competitive Scenario
      • 10.7.4.3. Regulatory Scenario
      • 10.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.5. Chile
      • 10.7.5.1. Key Country Dynamics
      • 10.7.5.2. Competitive Scenario
      • 10.7.5.3. Regulatory Scenario
      • 10.7.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.8. Middle East
    • 10.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.2. Saudi Arabia
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Scenario
      • 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.3. UAE
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Scenario
      • 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.4. Kuwait
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Scenario
      • 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.5. Egypt
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Scenario
      • 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.6. Israel
      • 10.8.6.1. Key Country Dynamics
      • 10.8.6.2. Competitive Scenario
      • 10.8.6.3. Regulatory Scenario
      • 10.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.9. Africa
    • 10.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.2. South Africa
      • 10.9.2.1. Key Country Dynamics
      • 10.9.2.2. Competitive Scenario
      • 10.9.2.3. Regulatory Scenario
      • 10.9.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.3. Botswana
      • 10.9.3.1. Key Country Dynamics
      • 10.9.3.2. Competitive Scenario
      • 10.9.3.3. Regulatory Scenario
      • 10.9.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.4. Namibia
      • 10.9.4.1. Key Country Dynamics
      • 10.9.4.2. Competitive Scenario
      • 10.9.4.3. Regulatory Scenario
      • 10.9.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.5. Zimbabwe
      • 10.9.5.1. Key Country Dynamics
      • 10.9.5.2. Competitive Scenario
      • 10.9.5.3. Regulatory Scenario
      • 10.9.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.6. Zambia
      • 10.9.6.1. Key Country Dynamics
      • 10.9.6.2. Competitive Scenario
      • 10.9.6.3. Regulatory Scenario
      • 10.9.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.7. Tanzania
      • 10.9.7.1. Key Country Dynamics
      • 10.9.7.2. Competitive Scenario
      • 10.9.7.3. Regulatory Scenario
      • 10.9.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.8. Rwanda
      • 10.9.8.1. Key Country Dynamics
      • 10.9.8.2. Competitive Scenario
      • 10.9.8.3. Regulatory Scenario
      • 10.9.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.9. Ghana
      • 10.9.9.1. Key Country Dynamics
      • 10.9.9.2. Competitive Scenario
      • 10.9.9.3. Regulatory Scenario
      • 10.9.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.10. Nigeria
      • 10.9.10.1. Key Country Dynamics
      • 10.9.10.2. Competitive Scenario
      • 10.9.10.3. Regulatory Scenario
      • 10.9.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.11. Uganda
      • 10.9.11.1. Key Country Dynamics
      • 10.9.11.2. Competitive Scenario
      • 10.9.11.3. Regulatory Scenario
      • 10.9.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.12. Mauritius
      • 10.9.12.1. Key Country Dynamics
      • 10.9.12.2. Competitive Scenario
      • 10.9.12.3. Regulatory Scenario
      • 10.9.12.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.9.13. Kenya
      • 10.9.13.1. Key Country Dynamics
      • 10.9.13.2. Competitive Scenario
      • 10.9.13.3. Regulatory Scenario
      • 10.9.13.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Competitive Market Assessment Analysis (2023)
  • 11.3. Service Heat Map Analysis (a comparative analysis of the players together)
  • 11.4. Company Profiles
    • 11.4.1. Freyr
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Financial Performance
      • 11.4.1.3. Service Benchmarking
      • 11.4.1.4. Strategic Initiatives
    • 11.4.2. IQVIA Inc.
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Financial Performance
      • 11.4.2.3. Service Benchmarking
      • 11.4.2.4. Strategic Initiatives
    • 11.4.3. ICON plc.
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Financial Performance
      • 11.4.3.3. Service Benchmarking
      • 11.4.3.4. Strategic Initiatives
    • 11.4.4. WuXi AppTec (WAI)
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Financial Performance
      • 11.4.4.3. Service Benchmarking
      • 11.4.4.4. Strategic Initiatives
    • 11.4.5. Charles River Laboratories International, Inc.
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Financial Performance
      • 11.4.5.3. Service Benchmarking
      • 11.4.5.4. Strategic Initiatives
    • 11.4.6. Labcorp Drug Development
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Financial Performance
      • 11.4.6.3. Service Benchmarking
      • 11.4.6.4. Strategic Initiatives
    • 11.4.7. Parexel International Corporation
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Financial Performance
      • 11.4.7.3. Service Benchmarking
      • 11.4.7.4. Strategic Initiatives
    • 11.4.8. Pharmalex GmbH
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Financial Performance
      • 11.4.8.3. Service Benchmarking
      • 11.4.8.4. Strategic Initiatives
    • 11.4.9. Pharmexon
      • 11.4.9.1. Company Overview
      • 11.4.9.2. Financial Performance
      • 11.4.9.3. Service Benchmarking
      • 11.4.9.4. Strategic Initiatives
    • 11.4.10. Genpact
      • 11.4.10.1. Company Overview
      • 11.4.10.2. Financial Performance
      • 11.4.10.3. Service Benchmarking
      • 11.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 4 Global Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 6 Global Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 7 Global Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 8 Global Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 9 Global Pharmaceutical Regulatory Affairs, by Region, 2018 - 2030 (USD Million)
  • Table 10 North America Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 12 North America Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 13 North America Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 14 North America Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 15 North America Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 16 North America Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 17 U.S. Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 18 U.S. Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 19 U.S. Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 20 U.S. Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 21 U.S. Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 22 U.S. Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 23 Canada Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 24 Canada Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 25 Canada Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 26 Canada Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 27 Canada Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 28 Canada Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 29 Mexico Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 30 Mexico Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 31 Mexico Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 32 Mexico Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 33 Mexico Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 34 Mexico Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 35 Europe Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
  • Table 36 Europe Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 37 Europe Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 38 Europe Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 39 Europe Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 40 Europe Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 41 Europe Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 42 UK Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 43 UK Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 44 UK Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 45 UK Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 46 UK Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 47 UK Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 48 Germany Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 49 Germany Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 50 Germany Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 51 Germany Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 52 Germany Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 53 Germany Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 54 France Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 55 France Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 56 France Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 57 France Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 58 France Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 59 France Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 60 Italy Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 61 Italy Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 62 Italy Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 63 Italy Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 64 Italy Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 65 Italy Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 66 Spain Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 67 Spain Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 68 Spain Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 69 Spain Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 70 Spain Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 71 Spain Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 72 Denmark Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 73 Denmark Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 74 Denmark Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 75 Denmark Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 76 Denmark Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 77 Denmark Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 78 Norway Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 79 Norway Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 80 Norway Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 81 Norway Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 82 Norway Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 83 Norway Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 84 The Netherlands Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 85 The Netherlands Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 86 The Netherlands Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 87 The Netherlands Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 88 The Netherlands Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 89 The Netherlands Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 90 Switzerland Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 91 Switzerland Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 92 Switzerland Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 93 Switzerland Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 94 Switzerland Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 95 Switzerland Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 96 Sweden Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 97 Sweden Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 98 Sweden Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 99 Sweden Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 100 Sweden Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 101 Sweden Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 102 Asia Pacific Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
  • Table 103 Asia Pacific Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 104 Asia Pacific Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 105 Asia Pacific Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 106 Asia Pacific Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 107 Asia Pacific Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 108 Asia Pacific Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 109 Japan Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 110 Japan Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 111 Japan Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 112 Japan Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 113 Japan Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 114 Japan Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 115 China Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 116 China Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 117 China Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 118 China Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 119 China Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 120 China Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 121 India Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 122 India Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 123 India Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 124 India Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 125 India Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 126 India Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 127 Australia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 128 Australia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 129 Australia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 130 Australia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 131 Australia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 132 Australia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 133 South Korea Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 134 South Korea Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 135 South Korea Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 136 South Korea Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 137 South Korea Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 138 South Korea Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 139 Indonesia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 140 Indonesia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 141 Indonesia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 142 Indonesia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 143 Indonesia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 144 Indonesia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 145 Malaysia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 146 Malaysia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 147 Malaysia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 148 Malaysia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 149 Malaysia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 150 Malaysia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 151 Singapore Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 152 Singapore Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 153 Singapore Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 154 Singapore Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 155 Singapore Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 156 Singapore Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 157 Thailand Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 158 Thailand Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 159 Thailand Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 160 Thailand Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 161 Thailand Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 162 Thailand Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 163 Taiwan Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 164 Taiwan Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 165 Taiwan Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 166 Taiwan Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 167 Taiwan Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 168 Taiwan Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 169 Latin America Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
  • Table 170 Latin America Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 171 Latin America Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 172 Latin America Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 173 Latin America Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 174 Latin America Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 175 Latin America Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 176 Brazil Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 177 Brazil Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 178 Brazil Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 179 Brazil Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 180 Brazil Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 181 Brazil Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 182 Argentina Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 183 Argentina Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 184 Argentina Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 185 Argentina Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 186 Argentina Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 187 Argentina Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 188 Colombia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 189 Colombia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 190 Colombia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 191 Colombia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 192 Colombia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 193 Colombia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 194 Chile Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 195 Chile Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 196 Chile Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 197 Chile Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 198 Chile Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 199 Chile Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 200 Middle East Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
  • Table 201 Middle East Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 202 Middle East Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 203 Middle East Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 204 Middle East Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 205 Middle East Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 206 Middle East Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 207 Saudi Arabia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 208 Saudi Arabia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 209 Saudi Arabia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 210 Saudi Arabia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 211 Saudi Arabia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 212 Saudi Arabia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 213 UAE Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 214 UAE Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 215 UAE Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 216 UAE Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 217 UAE Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 218 UAE Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 219 Kuwait Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 220 Kuwait Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 221 Kuwait Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 222 Kuwait Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 223 Kuwait Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 224 Kuwait Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 225 Egypt Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 226 Egypt Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 227 Egypt Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 228 Egypt Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 229 Egypt Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 230 Egypt Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 231 Israel Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 232 Israel Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 233 Israel Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 234 Israel Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 235 Israel Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 236 Israel Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 237 Africa Pharmaceutical Regulatory Affairs, by Country, 2018 - 2030 (USD Million)
  • Table 238 Africa Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 239 Africa Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 240 Africa Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 241 Africa Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 242 Africa Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 243 Africa Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 244 South Africa Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 245 South Africa Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 246 South Africa Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 247 South Africa Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 248 South Africa Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 249 South Africa Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 250 Botswana Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 251 Botswana Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 252 Botswana Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 253 Botswana Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 254 Botswana Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 255 Botswana Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 256 Namibia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 257 Namibia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 258 Namibia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 259 Namibia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 260 Namibia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 261 Namibia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 262 Zimbabwe Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 263 Zimbabwe Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 264 Zimbabwe Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 265 Zimbabwe Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 266 Zimbabwe Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 267 Zimbabwe Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 268 Zambia Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 269 Zambia Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 270 Zambia Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 271 Zambia Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 272 Zambia Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 273 Zambia Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 274 Tanzania Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 275 Tanzania Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 276 Tanzania Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 277 Tanzania Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 278 Tanzania Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 279 Tanzania Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 280 Rwanda Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 281 Rwanda Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 282 Rwanda Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 283 Rwanda Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 284 Rwanda Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 285 Rwanda Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 286 Ghana Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 287 Ghana Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 288 Ghana Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 289 Ghana Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 290 Ghana Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 291 Ghana Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 292 Nigeria Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 293 Nigeria Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 294 Nigeria Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 295 Nigeria Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 296 Nigeria Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 297 Nigeria Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 298 Uganda Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 299 Uganda Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 300 Uganda Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 301 Uganda Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 302 Uganda Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 303 Uganda Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 304 Mauritius Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 305 Mauritius Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 306 Mauritius Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 307 Mauritius Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 308 Mauritius Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 309 Mauritius Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
  • Table 310 Kenya Pharmaceutical Regulatory Affairs, by Service Provider, 2018 - 2030 (USD Million)
  • Table 311 Kenya Pharmaceutical Regulatory Affairs, by Service, 2018 - 2030 (USD Million)
  • Table 312 Kenya Pharmaceutical Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
  • Table 313 Kenya Pharmaceutical Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
  • Table 314 Kenya Pharmaceutical Regulatory Affairs, by Development Phase, 2018 - 2030 (USD Million)
  • Table 315 Kenya Pharmaceutical Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1. Information Procurement
  • Fig. 2. Primary Research Pattern
  • Fig. 3. Market Research Approaches
  • Fig. 4. Value Chain-Based Sizing & Forecasting
  • Fig. 5. Market Formulation & Validation
  • Fig. 6. Pharmaceutical Regulatory Affairs, Market Segmentation
  • Fig. 7. Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9. SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10. Porter's Five Forces Analysis
  • Fig. 11. Regional Marketplace: Key Takeaways
  • Fig. 12. Global Pharmaceutical Regulatory Affairs, for In-house, 2018 - 2030 (USD Million)
  • Fig. 13. Global Pharmaceutical Regulatory Affairs, for Outsourcing, 2018 - 2030 (USD Million)
  • Fig. 14. Global Pharmaceutical Regulatory Affairs, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 15. Global Pharmaceutical Regulatory Affairs, for Legal Representation , 2018 - 2030 (USD Million)
  • Fig. 16. Global Pharmaceutical Regulatory Affairs, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 17. Global Pharmaceutical Regulatory Affairs, for Writing, 2018 - 2030 (USD Million)
  • Fig. 18. Global Pharmaceutical Regulatory Affairs, for Publishing, 2018 - 2030 (USD Million)
  • Fig. 19. Global Pharmaceutical Regulatory Affairs, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 20. Global Pharmaceutical Regulatory Affairs, for Other Services, 2018 - 2030 (USD Million)
  • Fig. 21. Global Pharmaceutical Regulatory Affairs, for Drugs, 2018 - 2030 (USD Million)
  • Fig. 22. Global Pharmaceutical Regulatory Affairs, for Innovator Drugs, 2018 - 2030 (USD Million)
  • Fig. 23. Global Pharmaceutical Regulatory Affairs, for Preclinical Innovator Drugs, 2018 - 2030 (USD Million)
  • Fig. 24. Global Pharmaceutical Regulatory Affairs, for Clinical Innovator Drugs, 2018 - 2030 (USD Million)
  • Fig. 25. Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Innovator Drugs, 2018 - 2030 (USD Million)
  • Fig. 26. Global Pharmaceutical Regulatory Affairs, for Generics Drugs, 2018 - 2030 (USD Million)
  • Fig. 27. Global Pharmaceutical Regulatory Affairs, for Preclinical Generics Drugs, 2018 - 2030 (USD Million)
  • Fig. 28. Global Pharmaceutical Regulatory Affairs, for Clinical Generics Drugs, 2018 - 2030 (USD Million)
  • Fig. 29. Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Generics Drugs, 2018 - 2030 (USD Million)
  • Fig. 30. Global Pharmaceutical Regulatory Affairs, for Biologics, 2018 - 2030 (USD Million)
  • Fig. 31. Global Pharmaceutical Regulatory Affairs, for Biotech, 2018 - 2030 (USD Million)
  • Fig. 32. Global Pharmaceutical Regulatory Affairs, for Preclinical Biotech, 2018 - 2030 (USD Million)
  • Fig. 33. Global Pharmaceutical Regulatory Affairs, for Clinical Biotech, 2018 - 2030 (USD Million)
  • Fig. 34. Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Biotech, 2018 - 2030 (USD Million)
  • Fig. 35. Global Pharmaceutical Regulatory Affairs, for ATMP, 2018 - 2030 (USD Million)
  • Fig. 36. Global Pharmaceutical Regulatory Affairs, for Preclinical ATMP, 2018 - 2030 (USD Million)
  • Fig. 37. Global Pharmaceutical Regulatory Affairs, for Clinical ATMP, 2018 - 2030 (USD Million)
  • Fig. 38. Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) ATMP, 2018 - 2030 (USD Million)
  • Fig. 39. Global Pharmaceutical Regulatory Affairs, for Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 40. Global Pharmaceutical Regulatory Affairs, for Preclinical Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 41. Global Pharmaceutical Regulatory Affairs, for Clinical Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 42. Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA) Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 43. Global Pharmaceutical Regulatory Affairs, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 44. Global Pharmaceutical Regulatory Affairs, for Neurology, 2018 - 2030 (USD Million)
  • Fig. 45. Global Pharmaceutical Regulatory Affairs, for Cardiology, 2018 - 2030 (USD Million)
  • Fig. 46. Global Pharmaceutical Regulatory Affairs, for Immunology, 2018 - 2030 (USD Million)
  • Fig. 47. Global Pharmaceutical Regulatory Affairs, for Others, 2018 - 2030 (USD Million)
  • Fig. 48. Global Pharmaceutical Regulatory Affairs, for Preclinical, 2018 - 2030 (USD Million)
  • Fig. 49. Global Pharmaceutical Regulatory Affairs, for Clinical, 2018 - 2030 (USD Million)
  • Fig. 50. Global Pharmaceutical Regulatory Affairs, for Post Market Approval (PMA), 2018 - 2030 (USD Million)
  • Fig. 51. Global Pharmaceutical Regulatory Affairs, for Small, 2018 - 2030 (USD Million)
  • Fig. 52. Global Pharmaceutical Regulatory Affairs, for Medium, 2018 - 2030 (USD Million)
  • Fig. 53. Global Pharmaceutical Regulatory Affairs, for Large, 2018 - 2030 (USD Million)
  • Fig. 54. Regional Outlook, 2023 & 2030
  • Fig. 55. North America Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56. U.S. Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57. Canada Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58. Mexico Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59. Europe Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60. UK Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61. Germany Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62. France Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63. Italy Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64. Spain Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65. Denmark Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66. Norway Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67. Netherlands Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68. Switzerland Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 69. Sweden Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70. Asia Pacific Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 71. Japan Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72. China Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73. India Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 74. Australia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 75. South Korea Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76. Indonesia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 77. Malaysia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78. Singapore Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79. Thailand Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 80. Taiwan Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81. Latin America Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82. Brazil Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 83. Argentina Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 84. Colombia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85. Chile Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 86. Middle East Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 87. Saudi Arabia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88. UAE Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 89. Kuwait Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 90. Egypt Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 91. Israel Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 92. Africa Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 93. South Africa Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94. Botswana Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 95. Namibia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 96. Zimbabwe Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97. Zambia Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 98. Tanzania Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 99. Rwanda Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100. Ghana Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 101. Nigeria Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 102. Uganda Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103. Mauritius Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 104. Kenya Pharmaceutical Regulatory Affairs Market Estimates and Forecasts, 2018 - 2030 (USD Million)